Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel radiopharmaceuticals for oncology and treatments for rare diseases such as Wilson Disease. The company’s pipeline includes advanced radiopharmaceutical candidates designed to target solid tumors for both imaging and therapeutic purposes. Key assets involve the clinical-stage MNPR-101-Zr for cancer imaging, MNPR-101-Lu for targeted therapy, and a late-stage drug ALXN1840 aimed at treating Wilson Disease, a rare genetic disorder. Monopar leverages its in-house expertise and licensing agreements to advance these compounds through clinical trials, addressing unmet medical needs in oncology and rare disease therapeutics. Headquartered in Wilmette, Illinois, Monopar plays a specialized role in the biotechnology sector by innovating precise, targeted therapies that combine molecular biology and radiopharmaceutical technology to diagnose and treat aggressive cancers and genetic disorders.